Stay updated on Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial
Sign up to get notified when there's something new on the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page.

Latest updates to the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page
- ChecktodayChange DetectedThe footer release label updates from v3.8.0 to v3.8.1, with no change to the study record history.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe footer now displays website revision v3.8.0 instead of v3.7.2.SummaryDifference0.1%

- Check28 days agoChange DetectedA site-wide NIH announcement has been added above the study record, describing a transition from the term “Artificial Intelligence” to “Super Intelligence.”SummaryDifference0.5%

- Check35 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check42 days agoChange DetectedThe site footer now displays release revision v3.7.1 instead of v3.7.0; the study record content is unchanged.SummaryDifference0.1%

- Check63 days agoChange DetectedA new revision entry, v3.7.0, was added to the Record History and the previous v3.6.6 entry was removed. This reflects an update to the page's version history.SummaryDifference0.1%

Stay in the know with updates to Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page.